{"name":"Ortho-McNeil Janssen Scientific Affairs, LLC","slug":"ortho-mcneil-janssen-scientific-affairs-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"OROS MPH","genericName":"OROS MPH","slug":"oros-mph","indication":"Attention-deficit/hyperactivity disorder (ADHD) in children and adults","status":"marketed"},{"name":"OROS MPH Tablets","genericName":"OROS MPH Tablets","slug":"oros-mph-tablets","indication":"Attention deficit hyperactivity disorder (ADHD) in children and adults","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Levofloxacin; Azithromycin","genericName":"Levofloxacin; Azithromycin","slug":"levofloxacin-azithromycin","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"OROS MPH","genericName":"OROS MPH","slug":"oros-mph","phase":"marketed","mechanism":"OROS MPH is an extended-release formulation of methylphenidate that provides sustained dopamine and norepinephrine reuptake inhibition throughout the day.","indications":["Attention-deficit/hyperactivity disorder (ADHD) in children and adults"],"catalyst":""},{"name":"Levofloxacin; Azithromycin","genericName":"Levofloxacin; Azithromycin","slug":"levofloxacin-azithromycin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"OROS MPH Tablets","genericName":"OROS MPH Tablets","slug":"oros-mph-tablets","phase":"marketed","mechanism":"OROS MPH is an extended-release formulation of methylphenidate that provides sustained dopamine and norepinephrine reuptake inhibition throughout the day.","indications":["Attention deficit hyperactivity disorder (ADHD) in children and adults"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxNTmZYN3RzaUV6emxRaTJ1dnBwVG9UbndLQzQwbUd5cjVBQ2NUMTc3YkFUaXV2STFndi1BQW9OQlA1MmEwYXBIZ3lJdms0UjNqcTVjRmstOTBfQmdyTnpxM3N2NldsMlk5VW5pQjNOVlhnalAyTW4xN09aNDFOQ2liWTVkUE9RVEZhcDF0X3VDWE5PMkJUNGJGSjFGSzlMN0x5YnVMdTZ4eWNxZ0lzZFRady0wT1N0ZFhUOHpiVnZOdjFLc2VUQzBCaUYtY3NjNjFFYWs3Z1RpTEZXZFVNeVFZUEtySDY4U0c5Sk9YMmU1WjA1NFU0czVUaE90N0VtWk0?oc=5","date":"2010-10-29","type":"trial","source":"PR Newswire","summary":"New Data Analyses on CONCERTA® Pediatric Treatment Include Insight on Handwriting Performance and Attention in ADHD - PR Newswire","headline":"New Data Analyses on CONCERTA® Pediatric Treatment Include Insight on Handwriting Performance and Attention in ADHD","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":2,"phase_1":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}